---
title: "Trulicity (dulaglutide) in type 2 diabetes: Pharmacology questions"
description: "Pharmacology questions on Trulicity (dulaglutide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pharmacokinetics. Questions: Do antibodies to Trulicity affect how well it works? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/pharmacology"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Trulicity (dulaglutide) in type 2 diabetes: Pharmacology questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Trulicity](https://uspl.lilly.com/trulicity/trulicity.html#pi)

Pharmacology questions that apply to every indication of Trulicity are on [Trulicity (dulaglutide), all indications: Pharmacology](https://www.evicenter.com/medical-information/trulicity/pharmacology).

## Pharmacokinetics

<a id="trulicity-antibodies"></a>

### Do antibodies to Trulicity affect how well it works?

Applies to: Glycemic control as an adjunct to diet and exercise in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “In glycemic control trials in adults with type 2 diabetes mellitus (monotherapy and combination therapy) [see Clinical Studies (14.2, 14.3)], during a treatment period ranging from 24 to 104 weeks, 64/3,907 (1.6%) of TRULICITY-treated patients developed anti-dulaglutide antibodies (referred to as anti-drug-antibodies (ADA)). Of the 64 TRULICITY-treated patients that developed ADA, 34 patients (0.9% of the overall population) developed dulaglutide-neutralizing antibodies, and 36 patients (0.9% of the overall population) developed antibodies against native GLP-1. There was no identified clinically significant effect of ADA on pharmacokinetics, pharmacodynamics, safety, or effectiveness of TRULICITY over the 24 to 104 week treatment duration in the trials in adults with type 2 diabetes mellitus.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20glycemic%20control%20trials%20in,with%20type%202%20diabetes%20mellitus.)

> “During the 26-week controlled period of the glycemic control trial in pediatric patients 10 years of age or older with type 2 diabetes mellitus [see Clinical Studies (14.6)], 4/101 (4%) of TRULICITY-treated pediatric patients developed ADA. Of the 4 pediatric patients that developed ADA, 1 patient (1% of the overall population) developed dulaglutide-neutralizing antibodies and 3 patients (3% of the overall population) developed antibodies against native GLP-1. During the 52-week postbaseline period of the same trial (through safety follow-up), 6/103 (6%) of TRULICITY-treated patients developed ADA. Of the 6 patients that developed ADA, 1 patient (1% of the overall population) developed dulaglutide-neutralizing antibodies and 4 patients (4% of the overall population) developed antibodies against native GLP-1. Because of the low occurrence of ADA, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of TRULICITY is unknown in pediatric patients.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=During%20the%2026%2Dweek%20controlled%20period,is%20unknown%20in%20pediatric%20patients.)

Note: The first passage concerns adults and the second pediatric patients 10 years of age and older.

## Related pages
- [Medical information: Trulicity (dulaglutide): Type 2 diabetes](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/safety)
- [Specific populations](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes/guidelines)
